Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition

Pasithea Therapeutics Corp (NASDAQ:KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory disorders.

Why It Is Important: Alpha-5's lead therapeutic candidate can potentially improve clinical outcomes in patients with ALS. Post-mortem studies support that and reproducible significant improvement in behavior and survival in the SOD1 mice model. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.